A comparison study of IFN-γ, ADA, and CA125 as the diagnostic parameters in tuberculous pleuritis  by Aoki, Y. et al.
Respiratory Medicine (1994) 88, 139-143 
A comparison study of IFN-y, ADA, and CA125 as 
the diagnostic parameters in tuberculous pleuritis 
Y. AOKI, 0. KATOH, Y. NAKANISHI*, S. KUROKI, AND H. YAMADA 
Department of Internal Medicine, Saga Medical School, l-l, Nabeshima 5- chome, Saga 849, and 
*Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, 3-I-1, Maidashi, 
Higashi-ku Fukuoka 812, Japan 
Adenosine deaminase in pleural fluid (pADA), CA125 in serum (sCA125), and IFN-y in pleural fluid 
(pIFN-7) were measured in patients with pleurisy of various causes to evaluate their diagnostic utility in 
tuberculous pleuritis (TBP). We studied 39 pleural fluid samples, including 11 TBP and 28 non-TBP. With 
both pADA and sCA125, although the median values were much higher in TBP than in non-TBP groups, 
there was considerable overlap between the two groups. The sensitivity, specificity, and diagnostic efficiency 
were 81.8%, 89.3%, and 87.2%, respectively, when pADA values of more than 45 U ml-’ were considered, and 
they were loo%, 75.0%, and 84.2%, respectively, when sCA125 values of more than 35 U ml-’ were 
considered. In contrast, pIFN-y values were significantly higher in TBP patients (5.8 & 3.0 IU ml-‘; 
mean & S.D.) than those in non-TBP patients (CO.3 IU ml-‘), leading to both a sensitivity and a specificity of 
100%. 
Introduction 
Tuberculous pleurisy has long been a subject of 
debate in the differential diagnosis of exudative 
pleural effusions. Several diagnostic approaches are 
generally employed by clinicians, but the diagnostic 
yields vary with the type of procedure involved. 
They are reported to be 25-70% for pleural fluid 
culture (l-3) 50-80% for histology of closed pleural 
biopsies, and 70-95% for combined histology and 
culture of biopsy specimens (2-5). 
The measurement of adenosine deaminase levels in 
pleural fluid makes a major contribution to the 
diagnosis of TBP, and many investigators have 
reported on its diagnostic utility (69). 
We have reported that CA125, widely known as a 
diagnostic marker for ovarian carcinoma, increased 
in the sera of both male and female patients with 
TBP. In our previous study, the mean serum CA125 
levels in 8 TBP patients were significantly higher 
(P<O.Ol) than those in 12 benign non-TBP patients 
(10). Therefore, we have measured both pADA and 
sCA125 routinely in patients with pleurisy as diag- 
nostic clues to TBP. 
It has also been reported that IFN-y levels in 
pleural fluids are significantly higher in TBP as 
compared with non-TBP patients (11,12). 
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To the best of our knowledge, however, there are 
no reports in which diagnostic efficiencies of these 
tests for TBP were compared. In the present study, 
we concurrently measured pADA, sCA125, and 
pIFN-y in patients with pleurisy caused by various 
underlying disorders, and compared diagnostic 
utilities of these parameters in the patients with 
tuberculous pleuritis. 
Patients and Methods 
PATIENTS 
We studied pleural fluid samples from 39 patients 
with pleurisy (April, 1989 to August, 1991). In these 
39 patients, the following underlying disorders were 
found: (1) tuberculous pleuritis in 11 patients, (2) 
malignant pleuritis in 11, (3) empyema in five, (4) 
parapneumonic effusion in five, (5) autoimmune dis- 
ease in four (6) transdative pleural effusion in three 
(Table 1). 
In 11 TBP patients, the diagnoses were confirmed 
by the isolation of Mycobacterium tuberculosis (seven 
patients), positive pleural biopsy (one patient), or 
both (three patients). One patient with biopsy evi- 
dence alone showed a positive PPD reaction, 
lymphocyte-rich fluid, and a favourable clinical 
response to anti-tuberculous agents. 
In 11 malignant pleuritis patients, pleural fluid 
cytologies were all positive for malignant cells. Nine 
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Table 1 Characteristics of the patients with pleural effu- 
sions 
Diseases No. of Patients 
Tuberculosis 
Non-tuberculosis 
Malignancy 
Empyema 
Parapneumonia 
Autoimmune diseases 
Transdate 
11 
28 
11 
5 
5 
4 
3 
had histologically confirmed primary lung cancer 
(squamous cell carcinoma in five patients, adenocar- 
cinema in two, and small cell carcinima in two), and 
another two patients had malignant effusions due to 
pleural metastases from gall bladder carcinoma and 
T cell lymphoma. 
In four autoimmune disease patients, the pleurisies 
were caused by rheumatoid arthritis (RA), polymyo- 
sitis (PM), polyarteritis nodosa (PN), and Wegener’s 
granulomatosis (WG) in one each. The predominant 
cell types were lymphocytic in RA and PM, and 
neutrophilic in PN and WC. 
The transdative effusions were caused by conges- 
tive heart failure in two patients and liver cirrhosis 
in one. 
400 
SAMPLING AND ASSAY 
Blood and pleural fluids were obtained before 
treatment, centrifuged immediately, and then kept at 
- 30°C until assay. 
pADA was measured by reduced nicotinamide 
adenine dinucleotide-linked kinetic assay (AD auto, 
Maruho, Japan), sCA125 by one step radiometric 
immunoassay (CA153 RIA kit, Centcor, Canada), 
and pIFN-y by enzyme immunoassay (Human y-IFN 
Test, CSL, Australia). 
STATISTICAL ANALYSIS 
Between the groups, the significance of the differ- 
ence was examined by Student’s t-test. The degree of 
association between the parameters was examined by 
the coefficient of correlation. 
Results 
pADA values were measured in 11 TBP patients 
(eight male, three female) and in 28 non-TBP patients 
(male 18, female 10). The results are shown in Fig. 1. 
pADA values in TBP patients ranged from 35 to 
75 U I-’ with a median of 58.6 U I- ‘. In 28 non-TBP 
patients, 25 showed the pADA values of less than 
37 U l- ‘, however, the values in the other three 
patients were 52 (empyema), 97 (empyema), and 
412 U l- ’ (T cell lymphoma). Although the median 
l 412: T-cell lymphoma 
l 97: Empyema 
i 
; l 52: Empyema ___--__---__------------ 
I  1 
TBP non-TBP 
(n = 11) (n = 28) 
Fig. I pADA levels in TBP and non-TBP patients. Dotted line indicates cut-off value (45 U 1-l). 
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Fig. 2 Combined measurement of pADA and sCA125 in 
TBP (0; n=7) and non-TBP (0; ~12) patients. Dotted 
lines indicate cut-off value for pADA (45 U 1-i) and 
sCA125 (35 U ml-‘). 
value in TBP was much higher than in non-TBP 
patients (25.9 U l-l), there was no significant 
difference between the two groups. 
In the present study, sCA125 levels were available 
in seven TBP patients (five male, two female) and in 
12 non-TBP patients (seven male, five female). In 
TBP patients, the values ranged from 35 to 600 U 
ml-‘. In nine out of 12 non-TBP patients (75%), 
the values were less than 35 U ml-’ (7-32 U ml-‘), 
which is considered normal in our laboratory. In 
another three patients, however, the values showed 
marked increases; they were 880 (transdate due to 
liver cirrhosis), 463 (lung cancer), and 193 U ml-’ 
(Wegener’s granulomatosis). The median value in 
TBP (70 U ml-‘) was much higher than in non- 
TBP (20 U ml-‘); however, there was no significant 
difference between the two groups. 
We examined whether the combined measurement 
of pADA and sCA125 is useful in the diagnosis of 
TBP. The results were obtained from seven TBP and 
12 non-TBP patients in whom both values were 
available (Fig. 2). In six of seven TBP patients 
(85.7%), both of the pADA and sCA125 were 
increased, while both of these two parameters did not 
increase in eight of 12 non-TBP patients (66.6%). No 
TBP patients were found to have showed both of 
these two parameters being less than cut-off values, 
and conversely there were no non-TBP patients in 
whom these values were both increased. In the TBP 
patients, there was no correlation between the pADA 
and sCA125 values (data not shown). 
pIFN-y levels in 39 patients are shown in Fig. 3. 
In TBP patients, the values ranged from 2.0 to 
12.1 IU ml-‘, with the mean f SD of 58 & 3.0 IU 
ml-‘. On the contrary, the values were all less than 
0.3 IU ml’ in 28 non-TBP patients. There was a 
significant difference between the two groups 
(PcO.01). In the TBP patients, there was no correla- 
tion between the pIFN-y and pADA values (data 
not shown). 
The diagnostic utilities of pADA, sCA125, and 
pIFN-y for TBP are shown in Table 2. For pADA, 
the sensitivity, specificity and the diagnostic effi- 
ciency were 81.3%, 89.3%, and 87.2%, respectively, 
when the value of more than 45 U l- ’ was con- 
sidered. For sCA125, they were lOO%, 75%, and 
84.2% when the value of more than 35 U ml-’ was 
considered. In contrast, pIFN-y measurement 
Tuberculosis Malignancy Autoimmune Transdates 
(n = 11) (n = 11) Empyema dieeases (n = 3) 
parapneumonias h = 4) 
(n = 10) 
Fig. 3 pIFN-y levels in TBP and non-TBP patients. Horizontal bars indicate mean ZL S.D. IFN-7 is significantly higher in 
TBP than in non-TBP patients (PcO.01). 
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Table 2 Diagnostic utilities of the parameters in tubercu- 
lous pleuritis 
Sensitivity Specificity Efficiency 
pADA* 9/11 (81.8%) 25/28 (89.3%) 34/39 (87.2%) 
sCA125t 717 (100%) 902 (75.0%) 16/19 (84.2%) 
pIFN-y 11111 (100%) 28/28 (100%) 39/39 (100%) 
*cut-off; 45 u 1-l. 
@It-OF, 35 u 1-l 
yielded both a sensitivity and a specificity of lOO%, 
leading to the diagnostic efficiency also of 100%. 
Discussion 
Tuberculous pleuritis is still a major cause of 
pleural exudates, with the prevalence being reported 
to be nearly 10% of all pleural effusions (13). In order 
to make a definite diagnosis, pleural fluid culture and 
pleural biopsy are generally needed. However, evi- 
dence of tuberculosis cannot be obtained with these 
tests in 5-30% of the patients with TBP (2-5). 
Nowadays, the measurement of ADA in pleural 
fluid, in addition to conventional tests, has been 
widely employed as an useful diagnostic examination 
in the vast majority of patients suspected of having 
TBP (69). In the present study, although pADA 
measurement was considered to be of value, some 
patients with diseases such as lymphoma or empyema 
also showed substantial increase in pADA value, in 
agreement with previous investigators (812). It has 
been reported that pADA increases in rheumatoid 
pleurisy (814) but the value did not increase in one 
RA patient in our study. In the previous reports 
dealing with pADA, the cut- off values ran from 30 to 
70 U l- ’ (6-9). No doubt the diagnostic utility varies 
considerably with the cut-off value employed. When 
the value was established at 45 U l- ’ in our study, 
the diagnostic efficiency of pADA for TBP was 
87.2%. One may be reminded that the utility of 
pADA measurement depends partly on the preva- 
lence of tuberculosis. Its elevation is considered not 
so diagnostic in a country with a low morbidity rate 
for tuberculosis (15); whereas it is considered very 
useful in a high prevalence area (9). 
CA125 was originally described by Bast et al. (16) 
as an antigen which is recognized by the monoclonal 
antibody ‘OC125’ obtained by immunizing mice with 
a human ovarian cancer cell line. We previously 
reported that sCA125 is a good diagnostic marker for 
TBP for the following reasons: (1) CA125 was 
increased significantly in the sera of both male and 
female TBP patients as compared with non-TBP 
patients (P<O.Ol); (2) No evidences of female genital 
neoplasia were found in TBP patients; (3) sCA125 
values returned to normal range following the treat- 
ment of TBP (P<O.Ol) (10). In the present study, the 
sensitivity was 100% for TBP with the cut-off value of 
35 U ml-’ (range; 35-600); however, the specificity 
was 75%, which was lower than that of our previous 
study. It is known that sCA125 increases not only in 
patients with ovarian cancer but also in those with 
liver cirrhosis, hepatoma (17), lung cancer (18), and 
other conditions. Therefore, the high specificity of 
sCA125 for TBP found in our previous study may 
be explained by the differences of the non-TBP 
population. Our previous study included neither 
malignancy nor liver cirrhosis in non-TBP group, 
whereas the present study included both of these 
causes of pleurisy. We do not know why sCA125 
increased in one pleurisy associated with Wegener’s 
granulomatosis. In the previous study, there was no 
correlation between the values of sCA125 and CA125 
in pleural effusions (pCA125) measured on TBP 
patients, and there were also no differences at all in 
pCA125 values between TBP and non-TBP patients 
(10). Therefore, we can not explain the possible 
mechanism by which sCA125 increases in TBP 
patients. Although the specificity of sCA125 in the 
present study was not as good as the previous one, we 
expect that sCA125 could be one of the diagnostic 
clues to TBP, particularly when measured together 
with pADA; so far as our present study is concerned, 
the positive predictive value and the negative predic- 
tive value of the combined measurements proved to 
be 100% in the diagnosis of tuberculous pleuritis. 
IFN-y plays an important role in the local cell- 
mediated immune reaction at the site of active 
inflammation (11,19). In tuberculous pleurisy, PPD- 
specific T-lymphocytes are selectively present in 
pleural spaces where the disease activity is exclusively 
high (20,21). Barnes et al. (22) reported that CD4+/ 
CDw29’ ‘memory T cells’ were concentrated in 
tuberculous pleural effusions, which proliferate vig- 
orously and produce high levels of IFN-), in response 
to the stimulation with PPD. It was recently reported 
by Shimokata et al. (11) and by Ribera et al. (12) that 
IFN-y increased prominently in tuberculous pleural 
effusions. Also in our study, pIFN-y values differed 
significantly (P<O.Ol) between TBP and non-TBP 
patients, and there was no overlap in the ranges 
between the two groups. We expect that pIFN-y also 
increases to some extent in lymphocytic pleural 
effusions found in RA or PM, however, the values 
did not show any increase in our study. In this 
respect, we must further investigate with more 
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patients, especially of lymphocyte-rich autoimmune 
pleurisy, to know whether pIFN-y measurement is 
invariably diagnostic for TBP. 
In conclusion, we believe that the measurement of 
pADA and/or sCA125 are useful in the diagnosis of 
TBP. In addition, pIFN-y measurement is recom- 
mended, if available, when clinicians are confronted 
with a pleurisy strongly suspected of TBP but as yet 
undetermined by any other means. 
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